Package Leaflet: Information for the User
Leflunomide Zentiva 20 mg film-coated tablets
leflunomide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet, you may need to read it again.
Contents of the pack and other information
Leflunomide Zentiva belongs to a group of medicines called antirheumatic medicines. It contains leflunomide as the active substance.
Leflunomide Zentiva is used to treat adult patients with active rheumatoid arthritis or active psoriatic arthritis.
The symptoms of rheumatoid arthritis include joint inflammation, swelling, difficulty moving, and pain. Other symptoms that affect the whole body include loss of appetite, fever, lack of energy, and anemia (reduction in the number of red blood cells in the blood).
The symptoms of active psoriatic arthritis include joint inflammation, swelling, difficulty moving, pain, red-colored patches, and scaly skin (skin lesions).
Do not take Leflunomide Zentiva
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start taking Leflunomide Zentiva
Males who want to have children should contact their doctor, who may advise them to stop treatment with Leflunomide Zentiva and take certain medications to quickly and sufficiently eliminate Leflunomide Zentiva from their body. In this case, a blood test will be necessary to ensure that Leflunomide Zentiva has been sufficiently eliminated from their body, and then they should wait at least 3 months before trying to have children.
Occasionally, Leflunomide Zentiva can cause some blood, liver, lung, or nerve problems in the arms or legs. It can also cause some severe allergic reactions (including drug rash with eosinophilia and systemic symptoms [DRESS]), or increase the risk of serious infections. For more information on these side effects, see section 4 (Possible side effects).
DRESS initially appears with symptoms similar to those of the flu and a skin rash on the face, followed by a widespread skin rash with fever, elevated liver enzyme levels in the blood, and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.
Your doctor will perform blood testsat regular intervals, before and during treatment with Leflunomide Zentiva, to monitor blood cells and liver function. Your doctor should also check your blood pressure regularly, as Leflunomide Zentiva may cause an increase in blood pressure.
Talk to your doctor if you experience chronic diarrhea of unknown origin. You may need to have additional tests to establish a differential diagnosis.
Children and adolescents
Leflunomide Zentiva is not recommended for use in children and adolescents under 18 years of age.
Using Leflunomide Zentiva with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This includes medicines obtained without a prescription.
This is especially important if you are taking:
If you are taking a non-steroidal anti-inflammatory medicine(NSAIDs) and/or corticosteroids, you may continue taking them after starting treatment with Leflunomide Zentiva.
Vaccinations
Talk to your doctor if you need to be vaccinated. Some vaccines cannot be given while you are being treated with Leflunomide Zentiva or for a certain period after stopping treatment.
Taking Leflunomide Zentiva with food, drink, and alcohol
Leflunomide Zentiva can be taken with or without food.
It is not recommended to consume alcohol during treatment with Leflunomide Zentiva. Alcohol consumption during treatment with Leflunomide Zentiva may increase the risk of liver damage.
Pregnancy and breast-feeding
Do nottake Leflunomide Zentiva if you are or think you may be pregnant. If you are pregnant or become pregnant while taking Leflunomide Zentiva, there is an increased risk of having a child with serious birth defects. Women of childbearing age must not take Leflunomide Zentiva without using reliable contraceptive measures.
Tell your doctor if you plan to become pregnant after stopping treatment with Leflunomide Zentiva, as it is necessary to ensure that there are no remaining amounts of Leflunomide Zentiva in your body before becoming pregnant. The elimination of the medicine from the body may take up to 2 years. This time period can be reduced to a few weeks by taking certain medicines that accelerate the elimination of Leflunomide Zentiva from the body.
In any case, before becoming pregnant, a blood test must be performed to confirm that Leflunomide Zentiva has been sufficiently eliminated from your body, and once this test has been performed, you should wait at least 1 month before becoming pregnant.
For more information on laboratory tests, contact your doctor.
If you suspect that you may be pregnant during treatment with Leflunomide Zentiva or in the 2 years after treatment, you must immediatelycontact your doctor for a pregnancy test. If the test confirms that you are pregnant, your doctor may suggest that you start treatment with certain medicines to quickly and sufficiently eliminate Leflunomide Zentiva from your body, thereby reducing the risk to your child.
Do nottake Leflunomide Zentiva while breast-feeding, as leflunomide passes into breast milk.
Driving and using machines
Leflunomide Zentiva may make you feel dizzy, which can affect your ability to concentrate and react. If this happens, do not drive or use machines.
Leflunomide Zentiva contains lactose
If your doctor has told you that you have an intolerance to some sugars, contact them before taking this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The usual initial dose of Leflunomide Zentiva is one 100 mg tablet per day for the first three days.
After this, most people need a dose of:
Swallowthe tablet wholeand with plenty of water.
It may take about 4 weeks or even longer before you start to feel better. Some patients may even notice a new improvement after 4 or 6 months of treatment.
Leflunomide Zentiva is usually taken for long periods of time.
If you take more Leflunomide Zentiva than you should
If you take more Leflunomide Zentiva than you should, talk to your doctor or go to the nearest hospital casualty department immediately. If possible, take the tablets or the package with you.
If you forget to take Leflunomide Zentiva
If you forget to take a dose, take it as soon as you remember, unless it is nearly time for your next dose. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.
Like all medicines, Leflunomide Zentiva can cause side effects, although not everybody gets them.
Tell your doctor immediatelyand stop taking Leflunomide Zentiva:
Tell your doctor immediatelyif you experience:
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Rare side effects (may affect up to 1 in 1,000 people)
Very rare side effects (may affect up to 1 in 10,000 people)
Other side effects can also occur, with a frequency that is not known, such as kidney failure, decrease in uric acid levels in the blood, pulmonary hypertension, male infertility (this effect is reversible once treatment with this medicine is stopped), cutaneous lupus (characterized by skin rash/erythema in areas of the skin exposed to light), psoriasis (new or worsening), and DRESS can occur with a frequency that is not known.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date refers to the last day of the month shown.
Blister: Store in the original package.
Bottle: Keep the bottle tightly closed.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Leflunomide Zentiva
Appearance of the Product and Package Contents
Leflunomide Zentiva 20 mg film-coated tablets are triangular, yellowish to ochre-colored tablets.
The tablets are marked with ZBQ on one side.
The tablets are packaged in blisters or bottles.
Available pack sizes are 30, 50 and 100 tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder
Zentiva k.s.
U kabelovny 130
102 37 Prague 10
Czech Republic
Manufacturer
Sanofi Winthrop Industrie
56, Route de Choisy au Bac
F-60205 Compiegne Cedex
France
For further information about this medicinal product, please contact the local representative of the marketing authorization holder.
Belgium Zentiva, k.s. Tel: +32 280 86 420 PV-Belgium@zentiva.com | Lithuania Zentiva, k.s. Tel: +370 52152025 PV-Lithuania@zentiva.com |
Bulgaria Zentiva, k.s. Tel: +359 2 805 72 08 PV-Bulgaria@zentiva.com | Luxembourg Zentiva, k.s. Tel: +352 208 82330 PV-Luxembourg@zentiva.com |
Czech Republic Zentiva, k.s. Tel: +420 267 241 111 PV-Czech-Republic@zentiva.com | Hungary Zentiva, k.s. Tel: +36 165 55 722 PV-Hungary@zentiva.com |
Denmark Zentiva, k.s. Tel: +45 787 68 400 PV-Denmark@zentiva.com | Malta Zentiva, k.s. Tel: +356 277 82 052 PV-Malta@zentiva.com |
Germany Zentiva Pharma GmbH Tel: +49 (0) 800 53 53 010 PV-Germany@zentiva.com | Netherlands Zentiva, k.s. Tel: +31 202 253 638 PV-Netherlands@zentiva.com |
Estonia Zentiva, k.s. Tel: +372 52 70308 PV-Estonia@zentiva.com | Norway Zentiva, k.s. Tel: +47 219 66 203 PV-Norway@zentiva.com |
Greece Zentiva, k.s. Tel: +30 211 198 7510 PV-Greece@zentiva.com | Austria Zentiva, k.s. Tel: +43 720 778 877 PV-Austria@zentiva.com |
Spain Zentiva, k.s. Tel: +34 931 815 250 PV-Spain@zentiva.com | Poland Zentiva Polska Sp. z o.o. Tel: +48 22 375 92 00 PV-Poland@zentiva.com |
France Zentiva France Tel: +33 (0) 800 089 219 PV-France@zentiva.com | Portugal Zentiva Portugal, Lda Tel: +351 210 601 360 PV-Portugal@zentiva.com |
Croatia Zentiva, k.s. Tel: +385 155 17 772 PV-Croatia@zentiva.com | Romania S.C. ZENTIVA S.A. Tel: +40 021 317 31 36 PV-Romania@zentiva.com |
Ireland Zentiva, k.s. Tel: +353 766 803 944 PV-Ireland@zentiva.com | Slovenia Zentiva, k.s. Tel: +386 360 00 408 PV-Slovenia@zentiva.com |
Iceland Zentiva, k.s. Tel: +354 539 0650 PV-Iceland@zentiva.com | Slovakia Zentiva, a.s. Tel: +421 2 3918 3010 PV-Slovakia@zentiva.com |
Cyprus Zentiva, k.s. Tel: +357 240 30 144 PV-Cyprus@zentiva.com | Sweden Zentiva, k.s. Tel: +46 840 838 822 PV-Sweden@zentiva.com |
Latvia Zentiva, k.s. Tel: +371 67893939 PV-Latvia@zentiva.com | United Kingdom Zentiva Pharma UK Limited Tel: +44 (0) 845 372 7101 PV-United-Kingdom@zentiva.com |
Date of Last Revision of this Leaflet:
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website http://www.ema.europa.eu/